Skip to main content

Table 4 Subgroup analysis according to PET timing and parameters

From: Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

Outcomes PET timing PET parameter Studies (n) Pooled hazard ratios 95% confidence interval I2 (%) P for subgroup difference
Disease-free survival Interim %ΔSUVmax 9 0.20 0.13–0.31 0 0.8539
   SUVmax 1 0.24 0.07–0.82 NA  
   CMR 2 0.31 0.07–1.37 32  
  Post-treatment %ΔSUVmax 2 0.16 0.05–0.48 0 0.5821
   %ΔSUVpeak 1 0.16 0.02–1.28 NA  
   %ΔMTV 1 0.39 0.19–0.79 NA  
   ΔSUVmax 2 0.38 0.19–0.78 0  
   CMR 3 0.25 0.12–0.50 0  
Overall survival Interim %ΔSUVmax 3 0.20 0.09–0.44 0 0.7303
   CMR 1 0.34 0.02–6.64 NA  
  Post-treatment SUVmax 1 0.30 0.11–0.81 NA 0.7373
   CMR 2 0.24 0.10–0.59 0  
  1. CMR complete response, MTV metabolic tumour volume, NA not applicable, SUV standardised uptake value